- Home
- AMOD vs LSTA Comparison
AMOD vs LSTA Comparison
Compare AMOD & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMOD
- LSTA
- Stock Information
- Founded
- AMOD 2014
- LSTA 1980
- Country
- AMOD United States
- LSTA United States
- Employees
- AMOD N/A
- LSTA N/A
- Industry
- AMOD
- LSTA Misc Health and Biotechnology Services
- Sector
- AMOD
- LSTA Health Care
- Exchange
- AMOD NYSE
- LSTA Nasdaq
- Market Cap
- AMOD 26.1M
- LSTA 31.2M
- IPO Year
- AMOD N/A
- LSTA N/A
- Fundamental
- Price
- AMOD $2.09
- LSTA $2.55
- Analyst Decision
- AMOD
- LSTA Strong Buy
- Analyst Count
- AMOD 0
- LSTA 1
- Target Price
- AMOD N/A
- LSTA $15.00
- AVG Volume (30 Days)
- AMOD 13.4M
- LSTA 24.3K
- Earning Date
- AMOD 01-01-0001
- LSTA 02-27-2025
- Dividend Yield
- AMOD N/A
- LSTA N/A
- EPS Growth
- AMOD N/A
- LSTA N/A
- EPS
- AMOD N/A
- LSTA N/A
- Revenue
- AMOD N/A
- LSTA N/A
- Revenue This Year
- AMOD N/A
- LSTA N/A
- Revenue Next Year
- AMOD N/A
- LSTA N/A
- P/E Ratio
- AMOD N/A
- LSTA N/A
- Revenue Growth
- AMOD N/A
- LSTA N/A
- 52 Week Low
- AMOD $1.32
- LSTA $2.19
- 52 Week High
- AMOD $13.49
- LSTA $4.20
- Technical
- Relative Strength Index (RSI)
- AMOD N/A
- LSTA 42.39
- Support Level
- AMOD N/A
- LSTA $2.41
- Resistance Level
- AMOD N/A
- LSTA $2.66
- Average True Range (ATR)
- AMOD 0.00
- LSTA 0.19
- MACD
- AMOD 0.00
- LSTA 0.01
- Stochastic Oscillator
- AMOD 0.00
- LSTA 42.06
About AMOD ALPHA MODUS HOLDINGS INC
Alpha Modus Holdings Inc is a technology company with a core focus on artificial intelligence in retail. It is engaged in creating, developing and licensing data-driven technologies to enhance consumers' in-store digital experience at the point of decision.
About LSTA Lisata Therapeutics Inc.
Lisata Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. Its product candidate, LSTA1, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively.